-
Mashup Score: 28BCMA-directed CAR T-cell Therapy in patients with multiple myeloma and CNS involvement - 17 day(s) ago
Key Points. BCMA-directed CART in patients with multiple myeloma and CNS involvement is feasible without excess neurotoxicityData suggests consideration fo
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy - 18 day(s) ago
Key Points+1q is associated with worse hematologic response rate and heme-EFS with daratumumab-based frontline therapy in AL amyloidosis.t(11;14) is no lon
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
1q+ by FISH is associated with worse hematologic response rate and heme-EFS with daratumumab-based frontline therapy in AL amyloidosis #mmsm #amyloidosis @rajshekharucms @ZanwarSaurabh https://t.co/ORRWG6I9FD
-
-
Mashup Score: 18
Blood Cancer Journal – Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Elranatamab monotherapy in the real-world setting in RRMM: French compassionate use program on behalf of the IFM. N=101, ORR 51%, CR 42%. I-year PFS and OS: 34% and 42% #mmsm #bmtsm @Florent_Malard @Mohty_EBMT @BloodCancerJnl https://t.co/vKKExv1Txx https://t.co/g7XBBHCAVf
-
-
Mashup Score: 16Impatient for Outpatient: Operationalizing Bispecific Antibodies for Multiple Myeloma in the Ambulatory Setting | JCO Oncology Practice - 19 day(s) ago
In the article that accompanies this editorial, Sandahl et al 1 describe the successful implementation of an outpatient-based workflow for teclistamab administration. Teclistamab, a bispecific antibody (bsAb) targeting both CD3 on T cells and B-cell maturation ant igen (BCMA) on plasma cells, was the first bsAb to receive US Food and Drug Administration (FDA) approval in relapsed/refractory (R/R) multiple myeloma (MM) on the basis of the results of the MajesTEC-1 trial. In updated results from this
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Impatient for Outpatient: Operationalizing Bispecific Antibodies for Multiple Myeloma in the Ambulatory Setting | JCO Oncology Practice @RahulBanerjeeMD #mmsm https://t.co/GNH6IGRwYO
-
-
Mashup Score: 20
PURPOSETeclistamab is initiated with a step-up dosing (SUD) schedule to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). Early teclistamab users commonly received SUD in a hospital …
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Outpatient Teclistamab step-up dosing (SUD) is safe and feasible. Among 57 patients, 18 developed CRS, mostly gr 1, and 2 ICANS. 18 needed hospitalization for <2 days #mms @SandahlTyler @myelomaMD @MayoMyeloma https://t.co/BvstnzM0Iz
-
-
Mashup Score: 27BCMA-directed CAR T-cell Therapy in patients with multiple myeloma and CNS involvement - 19 day(s) ago
Key Points. BCMA-directed CART in patients with multiple myeloma and CNS involvement is feasible without excess neurotoxicityData suggests consideration fo
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Anti-BCMA CAR T-cells Therapy in MM and CNS involvement. N=10, 7 received CNS-directed bridging. ORR 80%, >/=VGPR 70%, median PFS 6.3 and median OS 13.3 months #mmsm #bmtsm @mahrefat @DrKrinaPatel @BloodAdvances https://t.co/YnS1eN5WuP
-
-
Mashup Score: 20Outcome of Patients With Central Nervous System Multiple Myeloma (CNS-MM) Treated With CNS-Directed Radiation Therapy - 20 day(s) ago
MicroabstractMultiple myeloma involving the central nervous system (CNS-MM) has a poor prognosis. This retrospective study evaluated outcomes of 45 patients treated with CNS-directed radiation therapy. Six of these patients had survival ranging from 11.2 to 52.2 months from CNS-MM diagnosis. Thus, aggressive multimodality therapy shows promise in achieving durable CNS control and longer-term survival in a small subset of patients.
Categories: General Medicine News, Hem/OncsTweet-
Outcome of Patients With CNS Multiple Myeloma Treated With CNS-Directed XRT. N=45, median OS from dx: 3.7 months. In 21 evaluable patients for response, CR 66.7%, median OS 7.3 months #mmsm @BouthainaDabaja @PennyFangMD #mmsm @MDAndersonNews https://t.co/2fEU4Doglv
-
-
Mashup Score: 27BCMA-directed CAR T-cell Therapy in patients with multiple myeloma and CNS involvement - 20 day(s) ago
Key Points. BCMA-directed CART in patients with multiple myeloma and CNS involvement is feasible without excess neurotoxicityData suggests consideration fo
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Anti-BCMA CAR T-cells Therapy in MM and CNS involvement. N=10, 7 received CNS-directed bridging. ORR 80%, >/=VGPR 70%, median PFS 6.3 and median OS 13.3 months #mmsm #bmtsm @mahrefat @DrKrinaPatel @BloodAdvances https://t.co/YnS1eN5WuP
-
-
Mashup Score: 27BCMA-directed CAR T-cell Therapy in patients with multiple myeloma and CNS involvement - 20 day(s) ago
Key Points. BCMA-directed CART in patients with multiple myeloma and CNS involvement is feasible without excess neurotoxicityData suggests consideration fo
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet-
Anti-BCMA CAR T-cells Therapy in MM and CNS involvement. N=10, 7 received CNS-directed bridging. ORR 80%, >/=VGPR 70%, median PFS 6.3 and median OS 13.3 months #mmsm #bmtsm @mahrefat @DrKrinaPatel @BloodAdvances https://t.co/YnS1eN5WuP
-
-
Mashup Score: 46Highlights of ASH 2024: Focus on Multiple Myeloma - 25 day(s) ago
According to the Surveillance, Epidemiology, and End Results Program registry, approximately 36,000 patients are annually diagnosed with multiple m…
Source: opmed.doximity.comCategories: General Medicine News, Hem/OncsTweet-
Highlights of ASH 2024: Focus on Multiple Myeloma #bmtsm #mmsm #ASH24 https://t.co/2eoZptGt68 via @doximity
-
Anti-BCMA CAR T-cells Therapy in MM and CNS involvement. N=10, 7 received CNS-directed bridging. ORR 80%, >/=VGPR 70%, median PFS 6.3 and median OS 13.3 months #mmsm #bmtsm @mahrefat @DrKrinaPatel @BloodAdvances https://t.co/YnS1eN5WuP